Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Andriole

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Urology|April 19, 2020
Commentary RE: "Efficacy and Safety of a Dual Inhibitor of 5-Alpha-Reductase Types 1 and 2 (Dutasteride) in Men With Benign Prostatic Hyperplasia"Eric Kim, Gerald Andriole
BJU International|September 24, 2013
Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trialPaul F Pinsky, Howard L Parnes, Gerald Andriole
Urology|September 28, 2002
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaClaus G Roehrborn, Peter Boyle, J Curtis Nickel, et al.
The Journal of Urology|November 6, 2012
Surgeon variation in patient quality of life after radical prostatectomyArthur Hartz, Tao He, Seth Strope, et al.
Urology Practice|August 18, 2023
Integrating the Genomic Prostate Score into Clinical Practice WorkflowDavid Albala, Premal J Desai, Vahan Kassabian, et al.
BJU International|October 6, 2018
Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trialPaul F Pinsky, Eric Miller, Philip Prorok, et al.
The Prostate|April 18, 2023
Smoking and lower urinary tract symptoms in Reduction by Dutasteride of Prostate Cancer Events TrialJordan J Kramer, Lin Gu, Daniel Moreira, et al.
The Journal of Urology|September 21, 2021
Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) TrialJordan J Kramer, Lin Gu, Daniel Moreira, et al.
Clinical Prostate Cancer|March 26, 2004
Radiation therapy for increasing prostate-specific antigen levels after radical prostatectomyCarlos A Perez, Jeff M Michalski, Kathy Baglan, et al.
European Urology|June 5, 2012
Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trialRoberto L Muller, Leah Gerber, Daniel M Moreira, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Urology|April 19, 2020
Commentary RE: "Efficacy and Safety of a Dual Inhibitor of 5-Alpha-Reductase Types 1 and 2 (Dutasteride) in Men With Benign Prostatic Hyperplasia"Eric Kim, Gerald Andriole
BJU International|September 24, 2013
Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trialPaul F Pinsky, Howard L Parnes, Gerald Andriole
Urology|September 28, 2002
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaClaus G Roehrborn, Peter Boyle, J Curtis Nickel, et al.
The Journal of Urology|November 6, 2012
Surgeon variation in patient quality of life after radical prostatectomyArthur Hartz, Tao He, Seth Strope, et al.
Urology Practice|August 18, 2023
Integrating the Genomic Prostate Score into Clinical Practice WorkflowDavid Albala, Premal J Desai, Vahan Kassabian, et al.
BJU International|October 6, 2018
Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trialPaul F Pinsky, Eric Miller, Philip Prorok, et al.
The Prostate|April 18, 2023
Smoking and lower urinary tract symptoms in Reduction by Dutasteride of Prostate Cancer Events TrialJordan J Kramer, Lin Gu, Daniel Moreira, et al.
The Journal of Urology|September 21, 2021
Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) TrialJordan J Kramer, Lin Gu, Daniel Moreira, et al.
Clinical Prostate Cancer|March 26, 2004
Radiation therapy for increasing prostate-specific antigen levels after radical prostatectomyCarlos A Perez, Jeff M Michalski, Kathy Baglan, et al.
European Urology|June 5, 2012
Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trialRoberto L Muller, Leah Gerber, Daniel M Moreira, et al.
Pageof 6